The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / EULAR 2013: New RA Recommendations Address Combination Therapy Concerns

EULAR 2013: New RA Recommendations Address Combination Therapy Concerns

October 1, 2013 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
New RA Recommendations May Clear Up Controversy

You Might Also Like
  • EULAR Releases 2016 Recommendations on RA Management
  • Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
  • EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
Explore This Issue
October 2013
Also By This Author
  • Texting May Have a Role in Managing Rheumatology Patients

MADRID—The latest European League Against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis give a somewhat greater nod to the use of combination conventional disease-modifying antirheumatic drugs (DMARDs) than past recommendations did, but leaves monotherapy with methotrexate as a perfectly acceptable first-line treatment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The recommendations also keep all biologic DMARDs—such as tumor necrosis factor (TNF) inhibitors—as second-line treatments, according to a presentation by Josef Smolen, MD, chair of rheumatology at the Medical University of Vienna, who spoke on behalf of the 33-member task force that wrote the updated recommendations. He made his remarks in a presentation at the EULAR 2013 Annual European Congress of Rheumatology, held June 12–15.

The task force included an infectious disease specialist, a health economist, four patient representatives and three fellows who performed systematic literature reviews on synthetic DMARDs, biologic DMARDs, and safety concerns.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment Recommendations

The task force recommends that biological DMARDs should be started, along with methotrexate, in patients who don’t respond sufficiently to conventional DMARDs and have risk factors for bad outcome. Those biologics, the task force decided, can include TNF inhibitors, abatacept, or tocilizumab.

There has been “no preference given to any agent as a first biological,” Dr. Smolen said.

The task force also adjusted its recommendations on glucocorticoid use, now saying that “low-dose glucocorticoids should be considered as part of the initial treatment strategy (in combination with one or more conventional synthetic DMARDs) for up to six months, but should be tapered as rapidly as clinically feasible.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The task force’s recommendations also have a place for tofacitinib, saying it “may be considered after biological treatment has failed.” The recommendations were finalized before the European Medicines Agency refused marketing authorization for the drug. Tofacitinib has been approved in the U.S., Japan, and Russia.

“EULAR recommendations are of a general nature and not only intended for Europe,” Dr. Smolen said.

Changes from 2010 Recommendations

EULAR’s 2010 RA recommendations caused a stir when monotherapy was expressly recommended as first-line treatment over combination conventional synthetic DMARDs. Some rheumatologists in the field felt that the evidence justified a more prominent role for combination therapy.

In the latest recommendations, the task force recommends either “conventional synthetic DMARD monotherapy or combination therapy” in DMARD-naive patients.

“The 2010 recommendations did not intend to say that the use of combination conventional synthetic DMARD therapy was wrong, but only that it was not needed,” Dr. Smolen said. “The 2013 task force reiterates the evidence-based view that conventional synthetic DMARD monotherapy is effective.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates, Meeting Reports Tagged With: disease-modifying antirheumatic drugs, DMARDs, EULAR 2013, Methotrexate, Rheumatoid arthritis, therapyIssue: October 2013

You Might Also Like:
  • EULAR Releases 2016 Recommendations on RA Management
  • Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
  • EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
  • EULAR 2013: Researchers Expand Targets for PsA, OA Therapy

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)